AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Sep 2019 07:00 AM
RNS
Tagrisso is the only 1st-line treatment for EGFR-
30 Sep 2019 07:00 AM
RNS
Lynparza improved the time women lived without
23 Sep 2019 07:00 AM
RNS
Qtrilmet recommended for approval in EU by CHMP
18 Sep 2019 07:00 AM
RNS
AstraZeneca amends collaboration with Ironwood
09 Sep 2019 08:38 AM
RNS
Imfinzi is first immunotherapy to show both
04 Sep 2019 07:11 AM
RNS
Tagrisso approved in China as a 1st-line treatment
02 Sep 2019 03:00 PM
RNS
Total Voting Rights
02 Sep 2019 07:05 AM
RNS
Brilinta reduced the risk of cardiovascular events
02 Sep 2019 07:00 AM
RNS
Detailed results from Phase III DAPA-HF trial
29 Aug 2019 07:00 AM
RNS
Anifrolumab Phase III trial meets primary endpoint
28 Aug 2019 07:05 AM
RNS
Fasenra granted US Orphan Drug Designation for
28 Aug 2019 07:00 AM
RNS
Breztri Aerosphere Phase III ETHOS trial met
22 Aug 2019 07:00 AM
RNS
Roxadustat approved in China for the treatment of
22 Aug 2019 07:00 AM
RNS
AstraZeneca agrees to buy US FDA Priority Review
21 Aug 2019 07:00 AM
RNS
Update on the Phase III NEPTUNE trial
20 Aug 2019 07:00 AM
RNS
Farxiga met primary endpoint in landmark Phase III
19 Aug 2019 07:00 AM
RNS
Directorate Change
14 Aug 2019 07:00 AM
RNS
Lynparza Phase III PAOLA-1 trial met primary endpo
14 Aug 2019 07:00 AM
RNS
Calquence granted US Breakthrough Therapy Designat
09 Aug 2019 09:28 AM
RNS
Amendment: Tagrisso significantly improves overall
09 Aug 2019 07:00 AM
RNS
Tagrisso significantly improves overall survival
07 Aug 2019 07:00 AM
RNS
Lynparza Phase III PROfound trial in HRR*
05 Aug 2019 07:00 AM
RNS
Forxiga label updated in the EU in type-2 diabetes
01 Aug 2019 03:00 PM
RNS
Total Voting Rights
25 Jul 2019 07:00 AM
RNS
AZN: H1 2019 Results
15 Jul 2019 07:00 AM
RNS
Update on US regulatory decision for Farxiga
12 Jul 2019 07:00 AM
RNS
Imfinzi granted US Orphan Drug Designation for
01 Jul 2019 03:00 PM
RNS
Total Voting Rights
01 Jul 2019 07:00 AM
RNS
Fasenra receives positive EU CHMP opinion for self
01 Jul 2019 07:00 AM
RNS
Forxiga receives positive EU CHMP opinion for
27 Jun 2019 07:00 AM
RNS
Imfinzi improves overall survival at interim
19 Jun 2019 07:00 AM
RNS
Bevespi Aerosphere approved by the Japanese
19 Jun 2019 07:00 AM
RNS
Breztri Aerosphere (PT010) approved in Japan for
19 Jun 2019 07:00 AM
RNS
Lynparza approved in Japan for 1st-line
18 Jun 2019 07:00 AM
RNS
Lynparza approved in the EU for 1st-line
17 Jun 2019 07:00 AM
RNS
Calquence significantly prolonged the time patient
12 Jun 2019 04:45 PM
RNS
Publication of a Prospectus
06 Jun 2019 07:00 AM
RNS
Calquence Phase III ELEVATE-TN trial met primary
05 Jun 2019 12:36 PM
EQS
AstraZeneca: Where has all the cash gone?
03 Jun 2019 03:00 PM
RNS
Block listing Interim Review
03 Jun 2019 03:00 PM
RNS
Total Voting Rights
03 Jun 2019 07:00 AM
RNS
Lynparza nearly doubled time patients lived with
10 May 2019 07:00 AM
RNS
Pooled analyses of the roxadustat global Phase III
08 May 2019 02:00 PM
RNS
Director/PDMR Shareholding
08 May 2019 11:00 AM
RNS
Director Declaration
08 May 2019 07:00 AM
RNS
Trastuzumab deruxtecan demonstrated clinically
07 May 2019 07:00 AM
RNS
Calquence PhIII ASCEND trial met primary endpoint
03 May 2019 07:00 AM
RNS
Qternmet XR approved in the US for type-2 diabetes
01 May 2019 03:00 PM
RNS
Total Voting Rights
01 May 2019 12:00 PM
RNS
Director/PDMR Shareholding
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings